Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

Published:2020-10-20 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Alotaibi Ahmad S.,Yilmaz Musa,Loghavi Sanam,DiNardo Courtney,Borthakur Gautam,Kadia Tapan M.,Thakral Beenu,Pemmaraju Naveen,Issa Ghayas C.,Konopleva Marina,Short Nicholas J.,Patel Keyur,Tang Guilin,Ravandi Farhad,Daver Naval

Funder

University of Texas MD Anderson Cancer Center

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference11 articles.

1. Targeting FLT3 mutations in AML: review of current knowledge and evidence.;Daver;Leukemia.,2019

2. Secondary mutations as mediators of resistance to targeted therapy in leukemia.;Daver;Blood.,2015

3. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.;Cools;Cancer Res.,2004

4. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.;Piloto;Blood.,2007

5. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia.;McMahon;Cancer Discov.,2019

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emergence of clonal evolution with Philadelphia chromosome in acute myeloid leukemia after hypomethylation agents and BCL2 inhibitor treatment;The Kaohsiung Journal of Medical Sciences;2024-08-19

2. Overcoming Secondary Mutations of Type II Kinase Inhibitors;Journal of Medicinal Chemistry;2024-06-05

3. Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes;Cancer Cell International;2024-05-19

4. N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants;Bioorganic Chemistry;2024-02

5. Acute myeloid leukemia and myeloid sarcoma;Atlas of Hematopathology with 100 Case Studies;2024